Literature DB >> 29293363

Relation Between Hypoglycemia and Glycemic Variability in Type 2 Diabetes Patients with Insulin Therapy: A Study Based on Continuous Glucose Monitoring.

Fumi Uemura1, Yosuke Okada1, Keiichi Torimoto1, Yoshiya Tanaka1.   

Abstract

BACKGROUND: To determine the factors associated with hypoglycemia in patients with type 2 diabetes mellitus (T2DM) on insulin therapy.
METHODS: This retrospective study included 62 inpatients with T2DM on insulin therapy who underwent 5-day continuous glucose monitoring (CGM). We analyzed the relation between hypoglycemia (defined as blood glucose below 70 mg/dL, as determined by the CGM) and time spent in hypoglycemia with fasting blood glucose, mean blood glucose (MBG), standard deviation (SD), coefficient of variation, minimum blood glucose level, maximum blood glucose level, and the percent time spent with blood glucose levels of >180 mg/dL.
RESULTS: Twelve patients (19.4%) developed hypoglycemia, and most were maintained on mix insulin therapy alone. In the hypoglycemic group, MBG was lower and SD was higher, than in the non-hypoglycemic group, although HbA1c was not different. Multivariate logistic regression analysis identified MBG and SD as factors related to hypoglycemia. Receiver operating characteristic curve analysis showed that the optimal MBG and SD cutoff values for prediction of hypoglycemia were 150.9 and 41.1 mg/dL, respectively. When subjects were divided into four groups according to these values, time at blood glucose <70 mg/dL was longest, and total insulin dosage highest, in the MBG-low/SD-high group.
CONCLUSIONS: MBG and SD of glucose levels were identified as significant and independent determinants of hypoglycemia in T2DM on insulin therapy. It is important to use the least insulin dose, with the target of minimizing glycemic variability, to achieve good glycemic control without hypoglycemia.

Entities:  

Keywords:  Continuous glucose monitoring; Hypoglycemia; Insulin therapy; Type 2 diabetes

Mesh:

Substances:

Year:  2018        PMID: 29293363     DOI: 10.1089/dia.2017.0306

Source DB:  PubMed          Journal:  Diabetes Technol Ther        ISSN: 1520-9156            Impact factor:   6.118


  10 in total

1.  Hypoglycemia Incidence and Factors Associated in a Cohort of Patients With Type 2 Diabetes Hospitalized in General Ward Treated With Basal Bolus Insulin Regimen Assessed by Continuous Glucose Monitoring.

Authors:  Ana María Gómez; Angélica Imitola Madero; Diana Cristina Henao Carrillo; Martín Rondón; Oscar Mauricio Muñoz; Maria Alejandra Robledo; Martín Rebolledo; Maira García Jaramillo; Fabian León Vargas; Guillermo Umpierrez
Journal:  J Diabetes Sci Technol       Date:  2019-01-24

2.  Comparison of CGM-Derived Measures of Glycemic Variability Between Pancreatogenic Diabetes and Type 2 Diabetes Mellitus.

Authors:  Channabasappa Shivaprasad; Yalamanchi Aiswarya; Shah Kejal; Atluri Sridevi; Biswas Anupam; Barure Ramdas; Kolla Gautham; Premchander Aarudhra
Journal:  J Diabetes Sci Technol       Date:  2019-07-07

3.  Largest Amplitude of Glycemic Excursion Calculating from Self-Monitoring Blood Glucose Predicted the Episodes of Nocturnal Asymptomatic Hypoglycemia Detecting by Continuous Glucose Monitoring in Outpatients with Type 2 Diabetes.

Authors:  Shoubi Wang; Zhenhua Tan; Ting Wu; Qingbao Shen; Peiying Huang; Liying Wang; Wei Liu; Haiqu Song; Mingzhu Lin; Xiulin Shi; Xuejun Li
Journal:  Front Endocrinol (Lausanne)       Date:  2022-04-14       Impact factor: 6.055

4.  Association of Blood Glucose Level and Glycemic Variability With Mortality in Sepsis Patients During ICU Hospitalization.

Authors:  Zongqing Lu; Gan Tao; Xiaoyu Sun; Yijun Zhang; Mengke Jiang; Yu Liu; Meng Ling; Jin Zhang; Wenyan Xiao; Tianfeng Hua; Huaqing Zhu; Min Yang
Journal:  Front Public Health       Date:  2022-04-29

Review 5.  Glycemic variability: adverse clinical outcomes and how to improve it?

Authors:  Zheng Zhou; Bao Sun; Shiqiong Huang; Chunsheng Zhu; Meng Bian
Journal:  Cardiovasc Diabetol       Date:  2020-07-04       Impact factor: 9.951

6.  Efficacy and safety of dual add-on therapy with dapagliflozin plus saxagliptin versus glimepiride in patients with poorly controlled type 2 diabetes on a stable dose of metformin: Results from a 52-week, randomized, active-controlled trial.

Authors:  Juan P Frias; Guillermo Gonzalez-Galvez; Eva Johnsson; Jill Maaske; Marcia A Testa; Donald C Simonson; Nalina Dronamraju; Ricardo Garcia-Sanchez; Anne L Peters
Journal:  Diabetes Obes Metab       Date:  2020-03-09       Impact factor: 6.577

7.  The Association of Hypoglycemia Assessed by Continuous Glucose Monitoring With Cardiovascular Outcomes and Mortality in Patients With Type 2 Diabetes.

Authors:  Wei Wei; Shi Zhao; Sha-Li Fu; Lan Yi; Hong Mao; Qin Tan; Pan Xu; Guo-Liang Yang
Journal:  Front Endocrinol (Lausanne)       Date:  2019-08-06       Impact factor: 5.555

8.  Enlarged glycemic variability in sulfonylurea-treated well-controlled type 2 diabetics identified using continuous glucose monitoring.

Authors:  Fumi Uemura; Yosuke Okada; Keiichi Torimoto; Yoshiya Tanaka
Journal:  Sci Rep       Date:  2021-03-01       Impact factor: 4.379

9.  Improved time in range and postprandial hyperglycemia with canagliflozin in combination with teneligliptin: Secondary analyses of the CALMER study.

Authors:  Kyu Yong Cho; Hiroshi Nomoto; Akinobu Nakamura; Shinichiro Kawata; Hajime Sugawara; Jun Takeuchi; So Nagai; Kazuno Omori; Kazuhisa Tsuchida; Aika Miya; Ikumi Shigesawa; Kenichi Tsuchida; Shingo Yanagiya; Hiraku Kameda; Hiroki Yokoyama; Shinji Taneda; Yoshio Kurihara; Shin Aoki; Naoki Nishimoto; Tatsuya Atsumi; Hideaki Miyoshi
Journal:  J Diabetes Investig       Date:  2021-02-05       Impact factor: 4.232

10.  Changes in endothelial function during educational hospitalization and the contributor to improvement of endothelial function in type 2 diabetes mellitus.

Authors:  Yukiko Goshima; Yosuke Okada; Keiichi Torimoto; Yoshihisa Fujino; Yoshiya Tanaka
Journal:  Sci Rep       Date:  2020-09-21       Impact factor: 4.379

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.